Clarus Therapeutics Receives U.S. FDA Approval of JATENZO (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- JATENZO is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men, and the first oral testosterone medicine approved in more than 60 years.
- 87 percent of hypogonadal men treated with JATENZO in the pivotal Phase 3 study had a mean total testosterone concentration in the normal range at the end of treatment